npj Parkinsons Disease

Papers
(The H4-Index of npj Parkinsons Disease is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Novel co-culture model of T cells and midbrain organoids for investigating neurodegeneration in Parkinson’s disease154
SVHRSP protects against rotenone-induced neurodegeneration in mice by inhibiting TLR4/NF-κB-mediated neuroinflammation via gut microbiota103
Author Correction: A framework for translational therapy development in deep brain stimulation101
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease94
Subthalamic nucleus deep brain stimulation alleviates oxidative stress via mitophagy in Parkinson’s disease85
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders83
Author Correction: MRgFUS subthalamotomy in Parkinson’s disease: an approach aimed at minimizing Lesion Volume82
Longitudinal corpus callosum microstructural decline in early-stage Parkinson’s disease in association with akinetic-rigid symptom severity81
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology81
Fiber-specific micro- and macroscopic white matter alterations in progressive supranuclear palsy and corticobasal syndrome78
Population fraction of Parkinson’s disease attributable to preventable risk factors77
Reorganization of intrinsic functional connectivity in early-stage Parkinson’s disease patients with probable REM sleep behavior disorder75
Author Correction: Neurocognitive correlates of semantic memory navigation in Parkinson’s disease73
Risk factors associated with age at onset of Parkinson’s disease in the UK Biobank71
Grey matter networks in women and men with dementia with Lewy bodies67
Transcriptome analysis in LRRK2 and idiopathic Parkinson’s disease at different glucose levels66
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease63
Empirical evidence for biometal dysregulation in Parkinson’s disease from a systematic review and Bradford Hill analysis62
Predictors of clinically significant quality of life impairment in Parkinson’s disease62
Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia61
Brainstem neuromelanin and iron MRI reveals a precise signature for idiopathic and LRRK2 Parkinson’s disease60
Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor54
Prospective controlled study on the effects of deep brain stimulation on driving in Parkinson’s disease54
Nigral glucose metabolism as a diagnostic marker of neurodegenerative parkinsonian syndromes53
Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism51
Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?51
Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures49
Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein48
Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies48
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease48
Ethnicity- and sex-specific genome wide association study on Parkinson’s disease47
Discovering genetic mechanisms underlying the co-occurrence of Parkinson’s disease and non-motor traits46
Expanding causal genes for Parkinson’s disease via multi-omics analysis45
Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease45
A multi-site study on sex differences in cortical thickness in non-demented Parkinson’s disease44
Transcriptomic imputation of genetic risk variants uncovers novel whole-blood biomarkers of Parkinson’s disease44
Occipital hypoperfusion and motor reserve in Parkinson’s disease: an early-phase 18F-FP-CIT PET study44
Assessing the clinical utility of inertial sensors for home monitoring in Parkinson’s disease: a comprehensive review43
rTMS improves dysphagia by inhibiting NLRP3 inflammasome activation and caspase-1 dependent pyroptosis in PD mice43
Comprehensive real time remote monitoring for Parkinson’s disease using Quantitative DigitoGraphy43
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI42
Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human alpha synuclein42
0.067795038223267